Teclistamab Impairs Detection of BCMA CAR-T Cells

Overview

Journal Blood Adv

Specialty Hematology

Date 2023 Apr 7

PMID 37026812

Authors

Bettina Glatte

Kerstin Wenk

Anja Grahnert

Maik Friedrich

Maximilian Merz

Vladan Vucinic

Luise Fischer

Kristin Reiche

Miriam Alb

Michael Hudecek

Paul Franz

Stephan Fricke

Uwe Platzbecker

Ulrike Koehl

Ulrich Sack

Andreas Boldt

Sunna Hauschildt

Ronald Weiss

Affiliations

Soon will be listed here.

Citing Articles

Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma.

Fandrei D, Seiffert S, Rade M, Rieprecht S, Gagelmann N, Born P Blood Cancer Discov. 2024; 6(1):38-54.

PMID: 39441177 PMC: 11707513. DOI: 10.1158/2643-3230.BCD-24-0118.

Evaluation of Anti-CAR Linker mAbs for CAR T Monitoring after BiTEs/bsAbs and CAR T-Cell Pretreatment.

Grahnert A, Seiffert S, Wenk K, Schmiedel D, Boldt A, Vucinic V Biomedicines. 2024; 12(8).

PMID: 39200107 PMC: 11351819. DOI: 10.3390/biomedicines12081641.

References

Bhaskar S, Dholaria B, Sengsayadeth S, Savani B, Oluwole O . Role of bridging therapy during chimeric antigen receptor T cell therapy. EJHaem. 2022; 3(Suppl 1):39-45. PMC: 9175845. DOI: 10.1002/jha2.335. View

Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li Y . Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020; 4(18):4538-4549. PMC: 7509877. DOI: 10.1182/bloodadvances.2020002393. View

Reichman A, Kunz A, Joedicke J, Hopken U, Keib A, Neuber B . Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells. Int J Mol Sci. 2022; 23(2). PMC: 8777942. DOI: 10.3390/ijms23020903. View

Chapuy C, Aguad M, Nicholson R, AuBuchon J, Cohn C, Delaney M . International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing. Transfusion. 2016; 56(12):2964-2972. DOI: 10.1111/trf.13789. View

Blache U, Weiss R, Boldt A, Kapinsky M, Blaudszun A, Quaiser A . Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications. Front Immunol. 2021; 12:658314. PMC: 8127837. DOI: 10.3389/fimmu.2021.658314. View

Tang Y, Yin H, Zhao X, Jin D, Liang Y, Xiong T . High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma. J Exp Clin Cancer Res. 2022; 41(1):2. PMC: 8722124. DOI: 10.1186/s13046-021-02214-z. View

Rollig C, Knop S, Bornhauser M . Multiple myeloma. Lancet. 2014; 385(9983):2197-208. DOI: 10.1016/S0140-6736(14)60493-1. View

Oostendorp M, Lammerts van Bueren J, Doshi P, Khan I, Ahmadi T, Parren P . When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion. 2015; 55(6 Pt 2):1555-62. DOI: 10.1111/trf.13150. View

Munshi N, Anderson Jr L, Shah N, Madduri D, Berdeja J, Lonial S . Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021; 384(8):705-716. DOI: 10.1056/NEJMoa2024850. View

10.

Murata K, McCash S, Carroll B, Lesokhin A, Hassoun H, Lendvai N . Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood. Clin Biochem. 2016; 51:66-71. PMC: 5360528. DOI: 10.1016/j.clinbiochem.2016.09.015. View

11.

Strassl I, Schreder M, Steiner N, Rudzki J, Agis H, Kunz T . The Agony of Choice-Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond. Cancers (Basel). 2021; 13(18). PMC: 8471156. DOI: 10.3390/cancers13184701. View

12.

Xiao X, Wang Y, Zou Z, Yang Y, Wang X, Xin X . Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies. Front Immunol. 2022; 13:954235. PMC: 9460961. DOI: 10.3389/fimmu.2022.954235. View